BioCryst resumes Peramivir Phase III

BCRX began enrolling U.S. patients in a Phase III study of Peramivir neuraminidase inhibitor

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE